Northpond Ventures GP, LLC's Form 4 filing
DICE Therapeutics, Inc.DICE · filed Sep 20, 2021
- Accession no.
- 0000899243-21-036646
- Filed
- Sep 20, 2021, 9:19 PM ET
- Trade date
- Sep 17, 2021
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 3 derivative transactions. Open-market purchases total $4.00M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Northpond Ventures GP, LLCCIK 0001867470 | 10% Owner |
| Northpond Ventures, LPCIK 0001867472 | 10% Owner |
| Rubin Michael P.CIK 0001867627 | 10% Owner |
| Northpond Ventures II GP, LLCCIK 0001869114 | 10% Owner |
| Northpond Ventures II, LPCIK 0001869128 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2021 | Common Stock | CConversionAcquired | +2,603,075 | –F1 | – | 2,603,075 | Indirect | |
| Sep 17, 2021 | Common Stock | CConversionAcquired | +454,796 | –F2 | – | 3,057,871 | Indirect | |
| Sep 17, 2021 | Common Stock | PPurchaseAcquired | +235,000 | $17.00 | +$3,995,000 | 3,292,871 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2021 | Common Stock | CConversionDisposed | −1,735,388 | –F1 | – | 0 | Indirect | |
| Sep 17, 2021 | Common Stock | CConversionDisposed | −867,687 | –F1 | – | 0 | Indirect | |
| Sep 17, 2021 | Common Stock | CConversionDisposed | −454,796 | –F2 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Immediately prior to the closing of the initial public offering of DICE Therapeutics, Inc. (the "Issuer"), each share of Series B Convertible Preferred Stock, par value $0.0001 per share (the "Series B Convertible Preferred Stock"), of the Issuer and each share of Series C Convertible Preferred stock, par value $0.0001 per share of the Issuer (the "Series C Convertible Preferred Stock") automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock"). The right to convert the Series B Convertible Preferred Stock and Series C Preferred Stock into Common Stock had no expiration date.
Referenced by the price of 1 transaction in Table I and 2 transactions in Table II.
- F2
Immediately prior to the closing of the initial public offering of the Issuer, each share of Series C-1 Convertible Preferred Stock, par value $0.0001 per share (the "Series C-1 Convertible Preferred Stock"), of the Issuer automatically converted on a one-for-one basis into shares of the Issuer's Common Stock. The right to convert the Series C-1 Convertible Preferred Stock had no expiration date.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.